# Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis

> **NCT05586230** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 32 (actual)

## Conditions studied

- Tuberculosis
- Rifampicin Resistant Tuberculosis

## Interventions

- **DRUG:** Pretomanid
- **DRUG:** Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB)

## Key facts

- **NCT ID:** NCT05586230
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-03
- **Primary completion:** 2026-05-02
- **Final completion:** 2026-05-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-05-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05586230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05586230, "Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT05586230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*